drugset / Trial / NCT01377974

Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis

NCT01377974

Phase 2 Completed 40 enrolled Brasilia University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.

Timeline

Start
2009-07
Primary completion
2013-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Meglumine antimonate Other / unclassified 20 mg/kg Intravenous
Subject Miltefosine Small molecule 50 mg Oral